Trial Profile
Study of drug-drug interactions (DDIs) among pDAAs and the concomitant medication associated to HCV patients in the usual clinical practice in Spain
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Nov 2020
Price :
$35
*
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary) ; Sofosbuvir/velpatasvir (Primary) ; Sofosbuvir/velpatasvir/voxilaprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 01 Oct 2020 Results (N=1286) to identify potential drug interactions between pangenotypic direct acting antivirals and concomitant cardiovascular therapies in patients with chronic hepatitis Cpublished in the Journal of International Medical Research
- 13 Dec 2018 New trial record
- 13 Nov 2018 Results presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases